-
公开(公告)号：US10548996B2
公开(公告)日：2020-02-04
申请号：US15300158
申请日：2015-03-30
发明人： Abdel Kareem Azab , Pilar de la Puente , Feda Azab
摘要： Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.
-
公开(公告)号：US20230142353A1
公开(公告)日：2023-05-11
申请号：US17916180
申请日：2021-03-30
CPC分类号： A61K9/0034 , A61K49/006 , A61P35/00 , A61P15/00 , A61K49/0032 , A61K47/10 , A61K33/243
摘要： A method of treating cervical cancer in a patient in need is described that includes implanting a fast release implant containing an effective amount of Cis-Pt within a cervical cancer lesion. The implant includes a polymer and a therapeutic load homogenously distributed throughout the polymer. The implant assumes a solid phase at room temperature and assumes a liquid phase at a body temperature of the patient.
-
公开(公告)号：US20200179520A1
公开(公告)日：2020-06-11
申请号：US16698068
申请日：2019-11-27
发明人： Abdel Kareem Azab , Barbara Muz
摘要： Among the various aspects of the present disclosure is the provision of compositions and methods for targeted treatment and imaging of cancers or tumors.
-
公开(公告)号：US20170232146A1
公开(公告)日：2017-08-17
申请号：US15585653
申请日：2017-05-03
CPC分类号： A61L27/3834 , A61L27/225 , A61L27/3608 , A61L27/3804 , A61L27/3808 , A61L27/3847 , A61L27/54 , A61L2300/414 , A61L2300/418 , A61L2300/42 , A61L2300/426 , A61L2300/64 , A61L2430/02 , A61L2430/40 , C12N5/0669 , C12N5/0694 , C12N2502/30 , C12N2513/00 , C12N2533/56 , G01N33/5011 , G01N33/5082 , G01N33/5088
摘要： A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
-
公开(公告)号：US20160299148A1
公开(公告)日：2016-10-13
申请号：US15038639
申请日：2014-11-24
发明人： Feda Azab , Barbara Muz , Abdel Kareem Azab
IPC分类号： G01N33/574 , C12N5/09
CPC分类号： G01N33/57492 , C12N5/0093 , C12N5/0694 , G01N33/57426 , G01N2333/70535 , G01N2333/70596
摘要： The present disclosure is directed to a molecular signature useful in the identification multiple myeloma cells. The molecular signature advantageously identifies multiple myeloma cells under both normoxic and hypoxic conditions. The disclosed molecular signature may be used to diagnose, prognose and monitor multiple myeloma.
摘要翻译： 本公开涉及可用于鉴定多发性骨髓瘤细胞的分子标记。 分子标记在正常氧和缺氧条件下有利地鉴定多发性骨髓瘤细胞。 所公开的分子特征可用于诊断，预后和监测多发性骨髓瘤。
-
6.发明申请3D TISSUE-ENGINEERED BONE MARROW FOR PERSONALIZED THERAPY AND DRUG DEVELOPMENT 有权用于个性化治疗和药物开发的三维组织工程骨髓瘤公开(公告)号：US20160136327A1
公开(公告)日：2016-05-19
申请号：US14942543
申请日：2015-11-16
CPC分类号： A61L27/3834 , A61L27/225 , A61L27/3608 , A61L27/3804 , A61L27/3808 , A61L27/3847 , A61L27/54 , A61L2300/414 , A61L2300/418 , A61L2300/42 , A61L2300/426 , A61L2300/64 , A61L2430/02 , A61L2430/40 , C12N5/0669 , C12N5/0694 , C12N2502/30 , C12N2513/00 , C12N2533/56 , G01N33/5011 , G01N33/5082 , G01N33/5088
摘要： A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
摘要翻译： 描述了一种用于患者个性化治疗的组织工程骨髓。 组织工程化骨髓包括自体纤维蛋白支架和从患者骨髓分离的多个患者来源的细胞。 自体纤维蛋白支架使用从患者骨髓分离的纤维蛋白原制成。 多个患者来源的细胞可以包括与血液或转移性恶性肿瘤相关的细胞，骨髓基质细胞和内皮细胞。 将患者衍生的细胞在自体纤维蛋白支架上培养以产生组织工程化骨髓。 组织工程骨髓可用于个性化药物筛选。
-
公开(公告)号：US20220387460A1
公开(公告)日：2022-12-08
申请号：US17776186
申请日：2020-11-11
发明人： Abdel Kareem Azab , Cinzia Federico
摘要： Compositions and methods of treatment for multiple myeloma (MM) are disclosed that include a liposome with a lipid bilayer shell enclosing a fluid-filled center, a targeting moiety coupled to the outer surface of the shell, a treatment compound disposed within the lipid bilayer shell or within the fluid-filled center, and an efficacy-enhancing compound disposed within the lipid bilayer shell or within the fluid-filled center. In some embodiments, the targeting moiety is PSGL-1, the proteasome-inhibiting compound is bortezomib, and the BMME-disrupting agent is a CXCR4 inhibitor or ROCK inhibitor.
-
公开(公告)号：US20200172629A1
公开(公告)日：2020-06-04
申请号：US16698285
申请日：2019-11-27
发明人： Abdel Kareem Azab , Kinan Alhallak
摘要： The present disclosure discloses compositions, and methods of making and using nanoparticles to treat cancer. Among the various aspects of the present disclosure is the provision of a nanoparticle composition and methods of using same. For example, the nanoparticle composition can comprise a nanoparticle and antibodies conjugated to the nanoparticle surface, an antibody can recognize an epitope on cancer cells (e.g., multiple myeloma), and another antibody can engage T cells.
-
公开(公告)号：US10463764B2
公开(公告)日：2019-11-05
申请号：US15585653
申请日：2017-05-03
IPC分类号： C12N5/074 , C12N5/0775 , A61L27/38 , A61L27/22 , G01N33/50 , C12N5/077 , C12N5/09 , A61L27/54 , A61L27/36
摘要： A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
-
公开(公告)号：US20170209606A1
公开(公告)日：2017-07-27
申请号：US15300158
申请日：2015-03-30
发明人： Abdel Kareem Azab , Pilar de la Puente , Feda Azab
CPC分类号： A61K51/1244 , A61K9/0019 , A61K51/06 , A61K51/065 , A61K51/1213
摘要： Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.019 秒)
